A Phase One Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism And Excretion Of [14C]PF-00299804 in Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 02 Apr 2011
At a glance
- Drugs Dacomitinib (Primary)
- Indications Head and neck cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 02 Apr 2011 Results will be presented at the Annual Meeting of the American Association for Cancer Research (AACR-2011).
- 11 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Feb 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.